Press Releases

  • Dec. 13, 2018 Bioasis to Present at Investor & Industry Conferences in January 2019

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that members of management will present at the following… Read more »

  • Dec. 10, 2018 Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors

    David M. Wurzer Appointed as Lead Director

  • Nov. 26, 2018 Bioasis Announces Voting Results for 2018 Annual and Special Meeting

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the voting results from its Annual & Special… Read more »

  • Nov. 20, 2018 Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™

    xB 3 -001 demonstrated lymphatic system penetration and more selective tissue distribution with xB 3 -001 than trastuzumab alone The Company has filed patent applications based on these observations and those data may have broader applicability An updated version of the corporate presentation is available for review at www.bioasis.us/investors

  • Oct. 30, 2018 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited… Read more »

  • Oct. 29, 2018 Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

    Under the terms of the agreement, Bioasis to receive a US$1 million upfront payment from Prothena, plus additional potential option exercise, regulatory and commercial milestone payments, plus additional royalties on net sales from licensed products Prothena will receive a worldwide, exclusive license to use the xB 3  platform with an undisclosed neurodegenerative disease target as well as the option for three additional neuroscience targets

  • Oct. 4, 2018 Bioasis Announces Investor Relations Service Agreement with Stern IR

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has engaged Stern Investor Relations, Inc. (“Stern… Read more »

  • Aug. 31, 2018 Bioasis Announces Stock Option Grants

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options… Read more »

  • Aug. 13, 2018 Bioasis Announces Closing of Previously Disclosed Private Placement

    THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

  • Jul. 30, 2018 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018

    RICHMOND, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »